Thrombopoietin Receptor Agonists Show Promise for Non-Muscle Myosin Heavy Chain 9-Related Disease

Non-muscle myosin heavy chain 9-related disease (MYH9-RD) is a rare, inherited disorder characterized by macrothrombocytopenia (abnormally large and few platelets), sensorineural hearing loss, cataracts, and progressive kidney disease. Current treatments are primarily supportive, focusing on managing symptoms like bleeding and renal complications, but do not address the underlying platelet dysfunction. This study addresses the critical lack of specific, effective therapies that can directly improve platelet counts and reduce bleeding risks in patients with MYH9-RD.

The study demonstrated that treatment with Romiplostim significantly improved hematological parameters in the MYH9-RD mouse model. Platelet counts in the treated group increased by an average of 2.5-fold compared to controls (p<0.001), reaching near-normal physiological levels in 80% of the treated animals by the end of the 4-week period. This increase was accompanied by a substantial reduction in bleeding episodes. Treated mice exhibited a 75% reduction in spontaneous bleeding events and a 50% decrease in tail bleeding time compared to untreated controls (p<0.01). Furthermore, markers of renal dysfunction, such as proteinuria, showed a 20% decrease in the treated group, suggesting a potential benefit beyond just platelet restoration. No significant adverse effects were observed during the treatment period, indicating good tolerability.